Cardiosense

Cardiosense develops a wearable sensor and AI platform for noninvasive cardiac monitoring, specifically designed to measure Pulmonary Capillary Wedge Pressure (PCWP), the best predictor of impending heart failure crises. The company's CardioTag sensor and PCWP Analysis Software have received FDA De Novo classification as class II medical devices, providing rapid quantitative PCWP readings in minutes at point-of-care, in clinics, or at home. The technology is validated against right heart catheterization with accuracy on par with implantable sensors. Cardiosense enables clinicians to manage heart failure weeks before fluid builds up, providing objective longitudinal hemodynamic data rather than simple notifications, supporting ED assessment and triage, inpatient management and discharge, and outpatient and at-home monitoring. Founded by engineers and scientists, the company leverages wearable technology, signal processing, and deep learning to convert raw physiological data into clinical intelligence. Founded in 2020 and headquartered in Chicago, United States, the company has raised approximately $15.1 million at the Series A stage.